Table 4.

Study objectives for trials exclusively for the elderly

	Trials exclusively for elderlya (%)	All other trials (%)	P-value
Toxicity	71	80	0.08
Efficacy	76	73	0.61
Progression-free survival	66	51	0.02
Overall survival	58	38	0.002
Biological parameters	10	29	0.001
Pharmacological parameters	15	20	0.31
Quality of life	18	7	0.002
Health care utilization	7	4	0.33
Completion of treatment	3	2	0.40
Functioning	2	0.7	0.42

^aTrials were considered as exclusively for the elderly if they exclude patients aged 60 years of age or younger.